Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Am I a moron? I just bought in.
stock should b at 7 on this news
bottomline drug has very clear and ez path for approval
morons start buying
Can't see it holding up after market open. A manufacturing problem means dead money for an UNKNOWN period. Market usually doesn't like UNKNOWNS.
Beautiful rebound into green
Ocular Therapeutix™ Receives Complete Response Letter from FDA for its NDA for DEXTENZA™ for the Treatment of Post-Surgic...
Date : 07/25/2016 @ 1:00PM
Back at ya Black. We should know today....I hope!
quat, SA put out very positive article today, so good luck.
I have straddles on this. Will sell the weak leg. The call on a CRL and the put on approval, then ride it out for...I hope... a nice profit.
quatd- I was going to hold thru on this one, but backed out mainly because of the price action. It has dropped into PDUFA and isn't recovering. LPCN and ELTP did the same and got a CRL. I will buy this on the dip if they get a CRL, otherwise I just will miss out on this potential ride. I have other binary events coming soon, some risky, some high percentage. Thx for the info, GLTU
Some of the Phase 111 data for OTX-DP was not real great. Ocul needs this approval badly as they have gone o for 2 in other trials and nothing much going after OTX-DP. I give it a 60-40 for approval. I agree it could pop to $7 on approval but stay alert. A CRL and this company could go into the dust pile of dead bios.
Just my thoughts.
Any longs here, make your mark if so. OCUL is trading just like PGNX did leading into PDUFA date. PGNX got approved. Will be interesting to see what happens here, but sorta looks like approval coming based on the trading pattern. Just maybe not huge sales expected so maybe that's why its not zooming up. Would probably hit around $7 on approval?? All IMHO
Any comments?
ZACKS upgrades OCUL to Buy rating
http://www.voicechronicle.com/34113-28-ocular-therapeutix-raised-to-buy-at-zacks-ocul/
MC 120MIL? Backing up the truck here. Doesnt Merril like this one too? Awesome opportunity on eye redness failure, IMO
Float is 13 million...shorts Sept 30/2015 was 2.3 million..may have gone over 3 million in October.
Days to cover (based on regular volume is 11-15 days.
Institutions hold the bulk of the shares...Shorts won't stay here long.
Co. has over 4$ a share in cash (June 30/2015)
The shorts have performed well & were on it hard last week
They will move on. Looking for a rebound to near 10$
I think the results, although ok, didn't paint a good financial model. For example, their glaucoma medicine did not meet a primary objective to remove redness in eyes. This is not a concern to the FDA, but most likely is to consumers who are looking for a quality product. Even with FDA approval, consumers still need to buy the product.
Basically, I think Ocular realized that they need to tweak their medicine to be competitive in the marketplace, and will require patience. The stock price reflects that.
The good news is that 4 analysts have the price as a buy and the other 2 list it as a hold. Personally, I was looking at buying at 9.40 (but thankfully didn't), but now I think the pps could go either way with bearish momentum being the catalyst for a price drop and bounce potential, overselling and long term potential of the company being a catalyst for a bounce. I'm going to watch the price on Monday and I may be tempted to buy if there is a bearish surge.
What happened here? I thought the Phase 2 and Phase 3 results were good. Or am I missing something?
That was an EXPENSIVE flight based on today's trading. Hard to tell where bottom is going to be... Could see this dropping all day and into next week, but it's hard to tell.
Sat down next to
the CEO today on my flight back to New England. Looks promising and looks like this is bottom
Are you holding this? looks interesting!
$OCUL recent news/filings
bullish
bullish divergence
bollinger band squeeze
## source: finance.yahoo.com
Fri, 15 May 2015 12:00:00 GMT ~ Ocular Therapeutix Inc Earnings Call scheduled for 8:00 am ET today
read full: http://biz.yahoo.com/cc/5/150255.html
*********************************************************
Fri, 15 May 2015 11:10:38 GMT ~ Ocular TherapeutixTM Announces Plans to Proceed with an NDA Submission for OTX-DP for Treatment of Post-Surgical Ocular Pain Indication; Reports First Quarter 2015 Financial Results
[at noodls] - Ocular TherapeutixTM Announces Plans to Proceed with an NDA Submission for OTX-DP for Treatment of Post-Surgical Ocular Pain Indication; Reports First Quarter 2015 Financial Results
read full: http://www.noodls.com/view/AA6D33C64125FF4B03B1DFC8BA3BA5D2C55068D0
*********************************************************
Fri, 15 May 2015 11:07:04 GMT ~ Q1 2015 Ocular Therapeutix Inc Earnings Release - Time Not Supplied
read full: http://biz.yahoo.com/research/earncal/20150515.html?t=ocul
*********************************************************
Fri, 15 May 2015 10:54:24 GMT ~ Ocular Therapeutix reports 1Q loss
read full: http://sg.finance.yahoo.com/news/ocular-therapeutix-reports-1q-loss-105424305.html
*********************************************************
Fri, 15 May 2015 10:54:24 GMT ~ Ocular Therapeutix reports 1Q loss
read full: http://finance.yahoo.com/news/ocular-therapeutix-reports-1q-loss-105424168.html
*********************************************************
$OCUL charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$OCUL company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/OCUL/company-info
Ticker: $OCUL
OTC Market Place: Not Available
CIK code: not found
Company name: Ocular Therapeutix, Inc.
Incorporated In:
Business Description: OTC Markets | Official site of the OTCQX, OTCQB and OTC Pink Marketplaces featuring Free Stock & Bond Quotes, Trade Prices, Chart, Financials and Company News & Information for Investors, Companies and Traders - OTCMarkets.com (window.NREUM||(NREUM={})).loader_config={xpid:"UwMGWVdSGwQIU1RQAgQ="};window.NREUM||(NREUM={}),__nr_require=function(t,e,n){function r(n){if(!e[n]){var o=e[n]={exports:{}};t[n][0].call(o.exports,function(e){var o=t[n][1][e];return r(o?o:e)},o,o.exports)}return e[n].exports}if("function"==typeof __nr_require)return __nr_require;for(var o=0;od;d++)c[d].apply(u,n);return u}function a(t,e){f[t]=s(t).concat(e)}function s(t){return f[t]||[]}function c(){return n(e)}var f={};return{on:a,emit:e,create:c,listeners:s,_events:f}}function r(){return{}}var o="nr@context",i=t("gos");e.exports=n()},{gos:"7eSDFh"}],ee:[function(t,e){e.exports=t("QJf3ax")},{}],3:[function(t){function e(t){try{i.console&&console.log(t)}catch(e){}}var n,r=t("ee"),o=t(1),i={};try{n=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(i.console=!0,-1!==n.indexOf("dev")&&(i.dev=!0),-1!==n.indexOf("nr_dev")&&(i.nrDev=!0))}catch(a){}i.nrDev&&r.on("internal-error",function(t){e(t.stack)}),i.dev&&r.on("fn-err",function(t,n,r){e(r.stack)}),i.dev&&(e("NR AGENT IN DEVELOPMENT MODE"),e("flags: "+o(i,function(t){return t}).join(", ")))},{1:23,ee:"QJf3ax"}],4:[function(t){function e(t,e,n,i,s){try{c?c-=1:r("err",[s||new UncaughtException(t,e,n)])}catch(f){try{r("ierr",[f,(new Date).getTime(),!0])}catch(u){}}return"function"==typeof a?a.apply(this,o(arguments)):!1}function UncaughtException(t,e,n){this.message=t||"Uncaught error with no additional information",this.sourceURL=e,this.line=n}function n(t){r("err",[t,(new Date).getTime()])}var r=t("handle"),o=t(6),i=t("ee"),a=window.onerror,s=!1,c=0;t("loader").features.err=!0,t(5),window.onerror=e;try{throw new Error}catch(f){"stack"in f&&(t(1),t(2),"addEventListener"in window&&t(3),window.XMLHttpRequest&&XMLHttpRequest.prototype&&XMLHttpRequest.prototype.addEventListener&&window.XMLHttpRequest&&XMLHttpRequest.prototype&&XMLHttpRequest.prototype.addEventListener&&!/CriOS/.test(navigator.userAgent)&&t(4),s=!0)}i.on("fn-start",function(){s&&(c+=1)}),i.on("fn-err",function(t,e,r){s&&(this.thrown=!0,n(r))}),i.on("fn-end",function(){s&&!this.thrown&&c>0&&(c-=1)}),i.on("internal-error",function(t){r("ierr",[t,(new Date).getTime(),!0])})},{1:10,2:9,3:7,4:11,5:3,6:24,ee:"QJf3ax",handle:"D5DuLP",loader:"G9z0Bl"}],5:[function(t){t("loader").features.ins=!0},{loader:"G9z0Bl"}],6:[function(t){function e(){}if(window.performance&&window.performance.timing&&window.performance.getEntriesByType){var n=t("ee"),r=t("handle"),o=t(1),i=t(2);t("loader").features.stn=!0,t(3),n.on("fn-start",function(t){var e=t[0];e instanceof Event&&(this.bstStart=Date.now())}),n.on("fn-end",function(t,e){var n=t[0];n instanceof Event&&r("bst",[n,e,this.bstStart,Date.now()])}),o.on("fn-start",function(t,e,n){this.bstStart=Date.now(),this.bstType=n}),o.on("fn-end",function(t,e){r("bstTimer",[e,this.bstStart,Date.now(),this.bstType])}),i.on("fn-start",function(){this.bstStart=Date.now()}),i.on("fn-end",function(t,e){r("bstTimer",[e,this.bstStart,Date.now(),"requestAnimationFrame"])}),n.on("pushState-start",function(){this.time=Date.now(),this.startPath=location.pathname+location.hash}),n.on("pushState-end",function(){r("bstHist",[location.pathname+location.hash,this.startPath,this.time])}),"addEventListener"in window.performance&&(window.performance.addEventListener("webkitresourcetimingbufferfull",function(){r("bstResource",[window.performance.getEntriesByType("resource")]),window.performance.webkitClearResourceTimings()},!1),window.performance.addEventListener("resourcetimingbufferfull",function(){r("bstResource",[window.performance.getEntriesByType("resource")]),window.performance.clearResourceTimings()},!1)),document.addEventListener("scroll",e,!1),document.addEventListener("keypress",e,!1),document.addEventListener("click",e,!1)}},{1:10,2:9,3:8,ee:"QJf3ax",handle:"D5DuLP",loader:"G9z0Bl"}],7:[function(t,e){function n(t){i.inPlace(t,["addEventListener","removeEventListener"],"-",r)}function r(t){return t[1]}var o=(t(1),t("ee").create()),i=t(2)(o),a=t("gos");if(e.exports=o,n(window),"getPrototypeOf"in Object){for(var s=document;s&&!s.hasOwnProperty("addEventListener");)s=Object.getPrototypeOf(s);s&&n(s);for(var c=XMLHttpRequest.prototype;c&&!c.hasOwnProperty("addEventListener");)c=Object.getPrototypeOf(c);c&&n(c)}else XMLHttpRequest.prototype.hasOwnProperty("addEventListener")&&n(XMLHttpRequest.prototype);o.on("addEventListener-start",function(t){if(t[1]){var e=t[1];"function"==typeof e?this.wrapped=t[1]=a(e,"nr@wrapped",function(){return i(e,"fn-",null,e.name||"anonymous")}):"function"==typeof e.handleEvent&&i.inPlace(e,["handleEvent"],"fn-")}}),o.on("removeEventListener-start",function(t){var e=this.wrapped;e&&(t[1]=e)})},{1:24,2:25,ee:"QJf3ax",gos:"7eSDFh"}],8:[function(t,e){var n=(t(2),t("ee").create()),r=t(1)(n);e.exports=n,r.inPlace(window.history,["pushState"],"-")},{1:25,2:24,ee:"QJf3ax"}],9:[function(t,e){var n=(t(2),t("ee").create()),r=t(1)(n);e.exports=n,r.inPlace(window,["requestAnimationFrame","mozRequestAnimationFrame","webkitRequestAnimationFrame","msRequestAnimationFrame"],"raf-"),n.on("raf-start",function(t){t[0]=r(t[0],"fn-")})},{1:25,2:24,ee:"QJf3ax"}],10:[function(t,e){function n(t,e,n){t[0]=o(t[0],"fn-",null,n)}var r=(t(2),t("ee").create()),o=t(1)(r);e.exports=r,o.inPlace(window,["setTimeout","setInterval","setImmediate"],"setTimer-"),r.on("setTimer-start",n)},{1:25,2:24,ee:"QJf3ax"}],11:[function(t,e){function n(){f.inPlace(this,p,"fn-")}function r(t,e){f.inPlace(e,["onreadystatechange"],"fn-")}function o(t,e){return e}function i(t,e){for(var n in t)e[n]=t[n];return e}var a=t("ee").create(),s=t(1),c=t(2),f=c(a),u=c(s),d=window.XMLHttpRequest,p=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"];e.exports=a,window.XMLHttpRequest=function(t){var e=new d(t);try{a.emit("new-xhr",[],e),u.inPlace(e,["addEventListener","removeEventListener"],"-",o),e.addEventListener("readystatechange",n,!1)}catch(r){try{a.emit("internal-error",[r])}catch(i){}}return e},i(d,XMLHttpRequest),XMLHttpRequest.prototype=d.prototype,f.inPlace(XMLHttpRequest.prototype,["open","send"],"-xhr-",o),a.on("send-xhr-start",r),a.on("open-xhr-start",r)},{1:7,2:25,ee:"QJf3ax"}],12:[function(t){function e(t){var e=this.params,r=this.metrics;if(!this.ended){this.ended=!0;for(var i=0;c>i;i++)t.removeEventListener(s,this.listener,!1);if(!e.aborted){if(r.duration=(new Date).getTime()-this.startTime,4===t.readyState){e.status=t.status;var a=t.responseType,f="arraybuffer"===a||"blob"===a||"json"===a?t.response:t.responseText,u=n(f);if(u&&(r.rxSize=u),this.sameOrigin){var d=t.getResponseHeader("X-NewRelic-App-Data");d&&(e.cat=d.split(", ").pop())}}else e.status=0;r.cbTime=this.cbTime,o("xhr",[e,r,this.startTime])}}}function n(t){if("string"==typeof t&&t.length)return t.length;if("object"!=typeof t)return void 0;if("undefined"!=typeof ArrayBuffer&&t instanceof ArrayBuffer&&t.byteLength)return t.byteLength;if("undefined"!=typeof Blob&&t instanceof Blob&&t.size)return t.size;if("undefined"!=typeof FormData&&t instanceof FormData)return void 0;try{return JSON.stringify(t).length}catch(e){return void 0}}function r(t,e){var n=i(e),r=t.params;r.host=n.hostname+":"+n.port,r.pathname=n.pathname,t.sameOrigin=n.sameOrigin}if(window.XMLHttpRequest&&XMLHttpRequest.prototype&&XMLHttpRequest.prototype.addEventListener&&!/CriOS/.test(navigator.userAgent)){t("loader").features.xhr=!0;var o=t("handle"),i=t(2),a=t("ee"),s=["load","error","abort","timeout"],c=s.length,f=t(1);t(4),t(3),a.on("new-xhr",function(){this.totalCbs=0,this.called=0,this.cbTime=0,this.end=e,this.ended=!1,this.xhrGuids={}}),a.on("open-xhr-start",function(t){this.params={method:t[0]},r(this,t[1]),this.metrics={}}),a.on("open-xhr-end",function(t,e){"loader_config"in NREUM&&"xpid"in NREUM.loader_config&&this.sameOrigin&&e.setRequestHeader("X-NewRelic-ID",NREUM.loader_config.xpid)}),a.on("send-xhr-start",function(t,e){var r=this.metrics,o=t[0],i=this;if(r&&o){var f=n(o);f&&(r.txSize=f)}this.startTime=(new Date).getTime(),this.listener=function(t){try{"abort"===t.type&&(i.params.aborted=!0),("load"!==t.type||i.called===i.totalCbs&&(i.onloadCalled||"function"!=typeof e.onload))&&i.end(e)}catch(n){try{a.emit("internal-error",[n])}catch(r){}}};for(var u=0;c>u;u++)e.addEventListener(s,this.listener,!1)}),a.on("xhr-cb-time",function(t,e,n){this.cbTime+=t,e?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof n.onload||this.end(n)}),a.on("xhr-load-added",function(t,e){var n=""+f(t)+!!e;this.xhrGuids&&!this.xhrGuids[n]&&(this.xhrGuids[n]=!0,this.totalCbs+=1)}),a.on("xhr-load-removed",function(t,e){var n=""+f(t)+!!e;this.xhrGuids&&this.xhrGuids[n]&&(delete this.xhrGuids[n],this.totalCbs-=1)}),a.on("addEventListener-end",function(t,e){e instanceof XMLHttpRequest&&"load"===t[0]&&a.emit("xhr-load-added",[t[1],t[2]],e)}),a.on("removeEventListener-end",function(t,e){e instanceof XMLHttpRequest&&"load"===t[0]&&a.emit("xhr-load-removed",[t[1],t[2]],e)}),a.on("fn-start",function(t,e,n){e instanceof XMLHttpRequest&&("onload"===n&&(this.onload=!0),("load"===(t[0]&&t[0].type)||this.onload)&&(this.xhrCbStart=(new Date).getTime()))}),a.on("fn-end",function(t,e){this.xhrCbStart&&a.emit("xhr-cb-time",[(new Date).getTime()-this.xhrCbStart,this.onload,e],e)})}},{1:"XL7HBI",2:13,3:11,4:7,ee:"QJf3ax",handle:"D5DuLP",loader:"G9z0Bl"}],13:[function(t,e){e.exports=function(t){var e=document.createElement("a"),n=window.location,r={};e.href=t,r.port=e.port;var o=e.href.split("://");return!r.port&&o[1]&&(r.port=o[1].split("/")[0].split("@").pop().split(":")[1]),r.port&&"0"!==r.port||(r.port="https"===o[0]?"443":"80"),r.hostname=e.hostname||n.hostname,r.pathname=e.pathname,r.protocol=o[0],"/"!==r.pathname.charAt(0)&&(r.pathname="/"+r.pathname),r.sameOrigin=!e.hostname||e.hostname===document.domain&&e.port===n.port&&e.protocol===n.protocol,r}},{}],14:[function(t,e){function n(t){return function(){r(t,[(new Date).getTime()].concat(i(arguments)))}}var r=t("handle"),o=t(1),i=t(2);"undefined"==typeof window.newrelic&&(newrelic=window.NREUM);var a=["setPageViewName","addPageAction","setCustomAttribute","finished","addToTrace","inlineHit","noticeError"];o(a,function(t,e){window.NREUM[e]=n("api-"+e)}),e.exports=window.NREUM},{1:23,2:24,handle:"D5DuLP"}],"7eSDFh":[function(t,e){function n(t,e,n){if(r.call(t,e))return t[e];var o=n();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(t,e,{value:o,writable:!0,enumerable:!1}),o}catch(i){}return t[e]=o,o}var r=Object.prototype.hasOwnProperty;e.exports=n},{}],gos:[function(t,e){e.exports=t("7eSDFh")},{}],handle:[function(t,e){e.exports=t("D5DuLP")},{}],D5DuLP:[function(t,e){function n(t,e,n){return r.listeners(t).length?r.emit(t,e,n):(o[t]||(o[t]=[]),void o[t].push(e))}var r=t("ee").create(),o={};e.exports=n,n.ee=r,r.q=o},{ee:"QJf3ax"}],id:[function(t,e){e.exports=t("XL7HBI")},{}],XL7HBI:[function(t,e){function n(t){var e=typeof t;return!t||"object"!==e&&"function"!==e?-1:t===window?0:i(t,o,function(){return r++})}var r=1,o="nr@id",i=t("gos");e.exports=n},{gos:"7eSDFh"}],G9z0Bl:[function(t,e){function n(){var t=p.info=NREUM.info,e=f.getElementsByTagName("script")[0];if(t&&t.licenseKey&&t.applicationID&&e){s(d,function(e,n){e in t||(t[e]=n)});var n="https"===u.split(":")[0]||t.sslForHttp;p.proto=n?"https://":"http://",a("mark",["onload",i()]);var r=f.createElement("script");r.src=p.proto+t.agent,e.parentNode.insertBefore(r,e)}}function r(){"complete"===f.readyState&&o()}function o(){a("mark",["domContent",i()])}function i(){return(new Date).getTime()}var a=t("handle"),s=t(1),c=(t(2),window),f=c.document,u=(""+location).split("?")[0],d={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",agent:"js-agent.newrelic.com/nr-632.min.js"},p=e.exports={offset:i(),origin:u,features:{}};f.addEventListener?(f.addEventListener("DOMContentLoaded",o,!1),c.addEventListener("load",n,!1)):(f.attachEvent("onreadystatechange",r),c.attachEvent("onload",n)),a("mark",["firstbyte",i()])},{1:23,2:14,handle:"D5DuLP"}],loader:[function(t,e){e.exports=t("G9z0Bl")},{}],23:[function(t,e){function n(t,e){var n=[],o="",i=0;for(o in t)r.call(t,o)&&(n=e(o,t[o]),i+=1);return n}var r=Object.prototype.hasOwnProperty;e.exports=n},{}],24:[function(t,e){function n(t,e,n){e||(e=0),"undefined"==typeof n&&(n=t?t.length:0);for(var r=-1,o=n-e||0,i=Array(0>o?0:o);++r
$OCUL share structure
## source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$OCUL extra dd links
Company name: Ocular Therapeutix, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/OCUL/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/OCUL/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=OCUL+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=OCUL+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=OCUL+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/OCUL/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/OCUL/news - http://finance.yahoo.com/q/h?s=OCUL+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/OCUL/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/OCUL/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/OCUL/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/OCUL/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/OCUL/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/OCUL/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/OCUL/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/OCUL/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=OCUL+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/OCUL
DTCC (dtcc.com): http://search2.dtcc.com/?q=Ocular+Therapeutix%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Ocular+Therapeutix%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Ocular+Therapeutix%2C+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/OCUL/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/OCUL
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/OCUL/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/OCUL/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/OCUL/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/OCUL/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/OCUL/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/OCUL/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/OCUL/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=OCUL&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=OCUL
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/OCUL/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=OCUL+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=OCUL+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=OCUL
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=OCUL
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=OCUL+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/OCUL/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=OCUL+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/OCUL.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=OCUL
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/OCUL/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/OCUL/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/OCUL/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/OCUL/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/OCUL
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/OCUL
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/OCUL:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=OCUL
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=OCUL
$OCUL DD Notes ~ http://www.ddnotesmaker.com/OCUL
Followers
|
34
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
235
|
Created
|
05/16/15
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |